JSEA  Vol.5 No.12 B , December 2012
Pharmacophore Model Generation of Thrombin Inhibitors
Thrombin, an important factor of clotting system, take part in a variety of physiological actions, such as blood clotting, anticoagulation, thrombosis and fibrinolysis. Inhibiting thrombin is a pivotal and effective step for the prophylaxis of venous and arterial thrombosis, as well as prevent myocardial infarction for high-risk patients. In this study, a three dimensional pharmacophore model was generated for the molecules which are responsible for vasodilation activities targeting thrombin. Ten compounds with known thrombin-inhibiting activity values were selected as training set to generate the hypothesis using GALAHAD program in SYBYL 7.0 software. The best hypothesis comprises five pharmacophore features: four hydrophobes groups and one positively charged group. It has been further validated towards a test set including known activity compounds obtained from Binding Database, the values of effectively active hit A% and comprehensive evaluation index CAI are respectively 63.33% and 2.34, the pharmacophore was proven to be successful in discriminating active and inactive inhibitors.  Furthermore, the pharmacophore model was used as a 3D query to screen TCMD (Version 2009) database and 6 hit compounds of higher predicted activity were the reported cardiovascular activities, which may be useful for further study.

Cite this paper
X. Wang, Y. Zhang, Y. Xiang, Z. Ren and Y. Qiao, "Pharmacophore Model Generation of Thrombin Inhibitors," Journal of Software Engineering and Applications, Vol. 5 No. 12, 2012, pp. 84-87. doi: 10.4236/jsea.2012.512B017.
[1]   Sambrano GR, Weiss EJ, Zheng YW, et al. “Role of thrombin signalling in platelets in haemostasis and thrombosis”. Nature, Vol. 413, No. 6, 2011, pp. 74-78. doi:10.1038/35092573

[2]   H LUO, Y LIANG. “Throm-bin-activatable fibrinolysis inhibitor: a new modulator linking coagulation and fibrinolysis”. Basic Medical Sciences and Clinics, Vol. 23, No. 5, 2003, pp. 484-489. doi:6325(2003)05-0484-06

[3]   Weitz JI. “Factor Xa and thrombin as targets for new oral anticoagulants”. Thrombosis Research, Vol. 127, No. 2, 2011, pp. S5-S12. doi:10.1016/S0049-3848(10)70147-X

[4]   Crawley JT, Zanardelli S, Chion CK, et al. “The central role of thrombin in hemostasis”. Journal of Thrombosis and Haemostasis,Vol. 5, Sup. s1, 2007,pp. 95-101. doi:10.1111/j.1538-7836.2007.02500.x

[5]   Nierodzik ML,Karpatkin S. “Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a throm-bin-regulated dormant tumor phenotype”. Cancer Cell, vol.10,No.5,2006, pp.355-362. doi.org/10.1016/j.ccr.2006.10.002

[6]   Bajzar L, Chan AK, Massicotte MP, et al. “Thrombosis in children with malignancy”. Current Opinion in Pediatrics,vol.18,No.1, 2006 ,pp.1-9. doi:10.1097/01.mop.0000193270.09001.ea

[7]   Eriksson BI, Quinlan DJ, Eikelboom JW. “Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Throm-boembolism”. Annual Review of Medicine, vol.62,2011,pp. 41-57. doi:10.1146/annurev-med-062209-095159

[8]   Bendel SD, Bona R, Baker WL. “Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation”. Advances in Therapy,vol.28,No.6,2011,pp.460-472. doi:10.1007/s12325-011-0025-1

[9]   A. Kobsar , J. Koess-ler , L. Kehrer,etal. “The thrombin inhibitors hirudin and Refludan? activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets”. Thrombo-sisandHaemostasis.Vol.107.No.3,2012,pp.521-529. doi:10.1160/TH11-07-0461

[10]   Steinmetzer T, Sturze-becher J. “Progress in the Development of Synthetic Thrombin Inhibitors as New Orally Active Anticoagu-lants”.Current Medicinal Chemistry,Vol.11,No.17, 2004,pp.2297-2321. doi:10.2174/0929867043364540

[11]   Santosh P, Gregory A. L., Julie E. P. “Conformation Mining:? An Algorithm for Finding Biologically Relevant Conformations”. J. Med. Chem., Vol. 48, No.9, 2005, pp. 3313-3318. doi:10.1021/jm049066l.

[12]   Milan Bruncko, William J. McClellan, Michael D. Wendt, et al. “Naphthamidine urokinase plasminogen activator inhibitors with im-proved pharmacokinetic properties”. Bioorganic & Me-dicinal Chemistry Letters, Vol.15,No.1, 2005, pp. 93-98. doi:10.1016/j.bmcl.2004.10.026

[13]   Petra ?tefanic Ander-luh, Marko Anderluh, Janez Ila?. “Toward a Novel Class of Antithrombotic Compounds with Dual Function. Dis-covery of 1,4-Benzoxazin-3(4H)-one Derivatives Pos-sessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic Activities”, J. Med. Chem., 2005, 48 (9), pp 3110–3113. doi:10.1021/jm048984g

[14]   Richmond, N.J., Abram, C.A., Wolohan, P.R., et al. “GALAHAD: 1 Pharmacophore Identification by Hypermolecular Alignment of Ligands in 3D”. J COMPUT AID MOL DES, Vol. 20, No. 9, 2006, pp. 567-587. doi:10.1007/s10822-006-9082-y.

[15]   N.J. Richmond, P.Willett, R.D. Clark. “Alignment of three-dimensionalmolecules using an image recognition algorithm”. J.Mol.Graph.Model. Vol. 23, No. 2, 2004, pp. 199-209. doi:10.1016/j.bbr.2011.03.031.